Gene expression analysis in mastocytosis reveals a highly consistent profile with candidate molecular markers

Journal of Allergy and Clinical Immunology

Volumn 112, Issue 6, 2003, Pages 1162-1170

  D'Ambrosio, Claudio ^a   Akin, Cem ^a   Wu, Yalin ^a   Magnusson, Magnus K ^b   Metcalfe, Dean D ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^b NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

Author keywords

Mastocytosis; Microarray; Tryptase

Indexed keywords

ACTIVATING TRANSCRIPTION FACTOR TYPE 3; ALPHA TRYPTASE; BETA TRYPTASE; CARBOXYPEPTIDASE A; GENE PRODUCT; MOLECULAR MARKER; MUSCLE APONEUROTIC FIBROSARCOMA TYPE F PROTEIN; RNA; TRYPTASE; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BONE MARROW CELL; CLINICAL ARTICLE; CLUSTER ANALYSIS; CONTROLLED STUDY; DISEASE MARKER; ENZYME BLOOD LEVEL; FEMALE; GENE EXPRESSION PROFILING; GENE IDENTIFICATION; HUMAN; HUMAN CELL; MALE; MASTOCYTOSIS; MONONUCLEAR CELL; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; RNA ANALYSIS; UPREGULATION;

EID: 0346995200     PISSN: 00916749     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jaci.2003.07.008     Document Type: Article

References (41)

1. Valent P, Horny HP, Escribano L, Longley BJ, Li CY, Schwartz LB, et al. Diagnostic criteria and classification of mastocytosis: a consensus proposal. Leukoc Res 2001;25:603-25.
2. Nagata H, Worobec AS, Oh CK, Chowdhury BA, Tannenbaum S, Suzuki Y, et al. Identification of a point mutation in the catalytic domain of the protooncogene c-kit in peripheral blood mononuclear cells of patients who have mastocytosis with an associated hematologic disorder. Proc Natl Acad Sci U S A 1995;92:10560-4.
3. Worobec AS, Semere T, Nagata H, Metcalfe DD. Clinical correlates of the presence of the Asp816Val c-kit mutation in the peripheral blood mononuclear cells of patients with mastocytosis. Cancer 1998;83:2120-9.
4. Longley BJ Jr, Metcalfe DD, Tharp M, Wang X, Tyrrell L, Lu SZ, et al. Activating and dominant inactivating c-KIT catalytic domain mutations in distinct clinical forms of human mastocytosis. Proc Natl Acad Sci U S A 1999;96:1609-14.
5. Akin C, Kirshenbaum AS, Semere T, Worobec AS, Scott LM, Metcalfe DD. Analysis of the surface expression of c-kit and occurrence of the c-kit Asp816Val activating mutation in T cells, B cells, and myelomonocytic cells in patients with mastocytosis. Exp Hematol 2000;28:140-7.
6. Yavuz SA, Lipsky PE, Yavuz S, Metcalfe DD, Akin C. Evidence for the involvement of an hematopoietic progenitor cell in systemic mastocytosis from single cell analysis of mutations in the c-kit gene. Blood 2002;100:661-5.
7. Longley BJ, Tyrrell L, Lu SZ, Ma YS, Langley K, Ding TG, et al. Somatic c-KIT activating mutation in urticaria pigmentosa and aggressive mastocytosis: establishment of clonality in a human mast cell neoplasm. Nat Genet 1996;12:312-4.
8. Valent P, Sperr WR, Samorapoompichit P, Geissler K, Lechner K, Horny HP, et al. Myelomastocytic overlap syndromes: biology, criteria, and relationship to mastocytosis. Leuk Res 2001;25:595-602.
9. Boyum A. Isolation of leucocytes from human blood: a two-phase system for removal of red cells with methylcellulose as erythrocyte-aggregating agent. Scand J Clin Lab Invest 1968;97(suppl):9-29.
10. Tamayo P, Slonim D, Mesirov J, Zhu Q, Kitareewan S, Dmitrovsky E, et al. Interpreting patterns of gene expression with self-organizing maps: methods and application to hematopoietic differentiation. Proc Natl Acad Sci U S A 1999;96:2907-12.
11. Schwartz LB, Irani AM, Roller K, Castells MC, Schechter NM. Quantitation of histamine, tryptase, and chymase in dispersed human T and TC mast cells. J Immunol 1987;138:2611-5.
12. Schwartz LB, Sakai K, Bradford TR, Ren S, Zweiman B, Worobec AS, et al. The α form of human tryptase is the predominant type present in blood at baseline in normal subjects and is elevated in those with systemic mastocytosis. J Clin Invest 1995;96:2702-10.
13. Tang BL, Low DY, Lee SS, Tan AE, Hong W. Molecular cloning and localization of human syntaxin 16, a member of the syntaxin family of SNARE proteins. Biochem Biophys Res Commun 1998;242:673-9.
14. Sattler M, Pride YB, Quinnan LR, Verma S, Malouf NA, Husson H, et al. Differential expression and signaling of CBL and CBL-B in BCR/ABL transformed cells. Oncogene 2002;21:1423-33.
15. Martin-Subero JI, Gesk S, Harder L, Sonoki T, Tucker PW, Schlegelberger B, et al. Recurrent involvement of the REL and BCL11A loci in classical Hodgkin lymphoma. Blood 2002;99:1474-7.
16. Yu L, Hui-chen F, Chen Y, Zou R, Yan S, Chun-xiang L, et al. Differential expression of RAB5A in human lung adenocarcinoma cells with different metastasis potential. Clin Exp Metastasis 1999;17:213-9.
17. Kataoka K, Yoshitomo-Nakagawa K, Shioda S, Nishizawa M. A set of Hox proteins interact with the Maf oncoprotein to inhibit its DNA binding, transactivation, and transforming activities. J Biol Chem 2001;276:819-26.
18. Yoshikawa K, Ogawa T, Baer R, Hemmi H, Honda K, Yamauchi A, et al. Abnormal expression of BRCA1 and BRCA1-interactive DNA-repair proteins in breast carcinomas. Int J Cancer 2000;88:28-36.
19. Robbins PF, el-Gamil M, Li YF, Topalian SL, Rivoltini L, Sakaguchi K, et al. Cloning of a new gene encoding an antigen recognized by melanoma-specific HLA-A24-restricted tumor-infiltrating lymphocytes. J Immunol 1995;154:5944-50.
20. Groffen J, Stephenson JR, Heisterkamp N, de Klein A, Bartram CR, Grosveld G. Philadelphia chromosomal breakpoints are clustered within a limited region, bcr, on chromosome 22. Cell 1984;36:93-9.
21. Kaufmann D, Leistner W, Kruse P, Kenner O, Hoffmeyer S, Hein C, et al. Aberrant splicing in several human tumors in the tumor suppressor genes neurofibromatosis type 1, neurofibromatosis type 2, and tuberous sclerosis 2. Cancer Res 2002;62:1503-9.
22. Muller S, van den Boom D, Zirkel D, Koster H, Berthold F, Schwab M, et al. Retention of imprinting of the human apoptosis-related gene TSSC3 in human brain tumors. Hum Mol Genet 2000;9:757-63.
23. Baker SJ, Reddy EP Modulation of life and death by the TNF receptor superfamily. Oncogene 1998;17:3261-70.
24. Xu SQ, El-Deiry WS. p21(WAF1/CIP1) inhibits initiator caspase cleavage by TRAIL death receptor DR4. Biochem Biophys Res Commun 2000;269:179-90.
25. Azam N, Vairapandi M, Zhang W, Hoffman B, Liebermann DA. Interaction of CR6 (GADD45-γ) with proliferating cell nuclear antigen impedes negative growth control. J Biol Chem 2001;276:2766-74.
26. Wu MY, Wang PY, Han SH, Hsieh SL. The cytoplasmic domain of the lymphotoxin-β receptor mediates cell death in HeLa cells. J Biol Chem 1999;274:11868-73.
27. Elson A. Protein tyrosine phosphatase ε increases the risk of mammary hyperplasia and mammary tumors in transgenic mice. Oncogene 1999;18:7535-42.
28. Lahti JM, Xiang J, Heath LS, Campana D, Kidd VJ. PITSLRE protein kinase activity is associated with apoptosis. Mol Cell Biol 1995;15:1-11.
29. Zellweger T, Miyake H, July LV, Akbari M, Kiyama S, Gleave ME. Chemosensitization of human renal cell cancer using antisense oligonucleotides targeting the antiapoptotic gene clusterin. Neoplasia 2001;3:360-7.
30. Gersuk GM, Beckham C, Loken MR, Kiener P, Anderson JE, Farrand A, et al. A role for tumour necrosis factor-α, Fas and Fas-Ligand in marrow failure associated with myelodysplastic syndrome. Br J Haematol 1998;103:176-88.
31. Raza A, Gezer S, Mundle S, Gao XZ, Alvi S, Borok R, et al. Apoptosis in bone marrow biopsy samples involving stromal and hematopoietic cells in 50 patients with myelodysplastic syndromes. Blood 1995;86:268-76.
32. Lin CW, Manshouri T, Jilani I, Neuberg D, Patel K, Kantarjian H, et al. Proliferation and apoptosis in acute and chronic leukemias and myelodysplastic syndrome. Leuk Res 2002;26:551-9.
33. Zang DY, Goodwin RG, Loken MR, Bryant E, Deeg HJ. Expression of tumor necrosis factor-related apoptosis-inducing ligand, Apo2L, and its receptors in myelodysplastic syndrome: effects on in vitro hemopoiesis. Blood 2001;98:3058-65.
34. Reynolds DS, Gurley DS, Stevens RL, Sugarbaker DJ, Austen KF, Serafin WE. Cloning of cDNAs that encode human mast cell carboxypeptidase A, and comparison of the protein with mouse mast cell carboxypeptidase A and rat pancreatic carboxypeptidases. Proc Natl Acad Sci USA 1989;86:9480-4.
35. Tsai FY, Orkin SH. Transcription factor GATA-2 is required for proliferation/survival of early hematopoietic cells and mast cell formation, but not for erythroid and myeloid terminal differentiation. Blood 1997;89:3636-43.
36. Castells MC, Irani AM, Schwartz LB. Evaluation of human peripheral blood leukocytes for mast cell tryptase. J Immunol 1987;138:2184-9.
37. Foster B, Schwartz LB, Devouassoux G, Metcalfe DD, Prussin C. Characterization of mast-cell tryptase-expressing peripheral blood cells as basophils. J Allergy Clin Immunol 2002;109:287-93.
38. Irani AA, Schechter NM, Craig SS, DeBlois G, Schwartz LB. Two types of human mast cells that have distinct neutral protease compositions. Proc Natl Acad Sci U S A 1986;83:4464-8.
39. Mashima T, Udagawa S, Tsuruo T. Involvement of transcriptional represser ATF3 in acceleration of caspase protease activation during DNA damaging agent-induced apoptosis. J Cell Physiol 2001;188:352-8.
40. Ishiguro T, Nagawa H. Expression of the ATF3 gene on cell lines and surgically excised specimens. Oncol Res 2000;12:181-3.
41. Fujiwara KT, Kataoka K, Nishizawa M. Two new members of the maf oncogene family, mafK and mafF, encode nuclear b-Zip proteins lacking putative trans-activator domain. Oncogene 1993;8:2371-80.